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INTRODUCTION
Since the introduction of the Biopharmaceutics Classifi-
cation System (BCS) (1), its validity and applicability have
been the subject of extensive research and discussion (2).
These efforts have resulted in an improved SUPAC-IR guid-
ance (3), a dissolution guidance (4), and a Food and Drug
Administration (FDA) guidance on waiver of in vivo bio-
equivalence studies for BCS Class I drugs in rapid dissolution
immediate-release (IR) solid oral-dosage forms (5). The BCS
guidance generally is considered to be conservative with re-
spect to the class boundaries of solubility and permeability in
addition to the dissolution criteria. Thus, the possibility modi-
fying these boundaries and criteria to allow waivers of in vivo
bioequivalence studies “biowaivers” for additional drug prod-
ucts has received increasing attention (6). In this commentary,
we present a discussion of the relevant scientific issues that
have been or will be examined when extensions of biowaivers
to additional IR solid oral drug products are considered. It is
hoped that this commentary will stimulate more discussion in




The BCS is a scientific framework for classifying a drug
substance based on its aqueous solubility and intestinal per-
meability (1). When combined with the in vitro dissolution
characteristics of the drug product, the BCS takes into ac-
count three major factors: solubility, intestinal permeability,
and dissolution rate, all of which govern the rate and extent of
oral drug absorption from IR solid oral-dosage forms (5).
The solubility classification of a drug in the BCS is based
on the highest dose strength in an IR product. A drug sub-
stance is considered highly soluble when the highest strength
is soluble in 250 mL or less of aqueous media over the pH
range of 1.0–7.5; otherwise, the drug substance is considered
poorly soluble. The volume estimate of 250 mL is derived
from typical bioequivalence study protocols that prescribe the
administration of a drug product to fasting human volunteers
with a glass (about 8 ounces) of water.
The permeability classification is based directly on the
extent of intestinal absorption of a drug substance in humans
or indirectly on the measurements of the rate of mass transfer
across the human intestinal membrane. Animal or in vitro
models capable of predicting the extent of intestinal absorp-
tion in humans may be used as alternatives, e.g., in situ rat
perfusion models and in vitro epithelial cell culture models. A
drug substance is considered highly permeable when the ex-
tent of intestinal absorption is determined to be 90% or
higher. Otherwise, the drug substance is considered to be
poorly permeable.
An IR drug product is characterized as a rapid-
dissolution product when not less than 85% of the labeled
amount of the drug substance dissolves within 30 min using
USP Apparatus I at 100 rpm or USP Apparatus II at 50 rpm
in a volume of 900 mL or less of each of the following media:
1) acidic media, such as 0.1 N HCl or USP simulated gastric
fluid without enzymes; 2) a pH 4.5 buffer; and 3) a pH 6.8
buffer or USP simulated intestinal fluid without enzymes.
Otherwise, the drug product is considered to be a slow dis-
solution product.
FDA GUIDANCE ON BIOWAIVERS
The FDA issued a guidance for industry on waivers of in
vivo bioavailability and bioequivalence studies for IR solid
oral-dosage forms based on the BCS in August 2000 (5). This
BCS guidance recommends that sponsors may request bio-
waivers for highly soluble and highly permeable drug sub-
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stances (Class I) in IR solid oral-dosage forms that exhibit
rapid in vitro dissolution, provided the following conditions
are met: 1) the drug must be stable in the gastrointestinal
tract; 2) excipients used in the IR solid oral-dosage forms
have no significant effect on the rate and extent of oral drug
absorption; 3) the drug must not have a narrow therapeutic
index; and 4) the product is designed not to be absorbed in the
oral cavity.
Based on the scientific principles of the BCS, observed in
vivo differences in the rate and extent of absorption of a drug
from two pharmaceutically equivalent solid oral products may
be due to in vivo differences in drug dissolution. When the in
vivo dissolution of an IR oral dosage form is rapid in relation
to gastric emptying, the rate and extent of drug absorption is
likely to be independent of drug dissolution. Therefore, simi-
lar to oral solutions, demonstration of in vivo bioequivalence
may not be necessary as long as the inactive ingredients used
in the dosage form do not significantly affect the absorption
of the active ingredient. Thus, for BCS Class I (high solubil-
ity-high permeability) drug substances, demonstration of
rapid in vitro dissolution using the recommended test meth-
ods would provide sufficient assurance of rapid in vivo disso-
lution, thereby ensuring human in vivo bioequivalence. In our
opinion, the potential benefit of this FDA guidance is not
only lowering expenditures associated with bioavailability/
bioequivalence studies but more critically expediting the de-
velopment of new chemical entities for the marketplace, en-
tities that will ultimately be of benefit to the health of the
American public.
BIOWAIVER EXTENSION POTENTIAL
Potential of Redefining BCS Solubility Class Boundary
The solubility class boundary requires that the highest
strength of a drug substance is soluble in 250 mL or less of
aqueous media over the pH range of 1.0–7.5. The pH range of
1.0–7.5 for solubility studies is a stringent requirement and
may not be necessary. Under fasting conditions, the pH range
in the GI tract vary from 1.4 to 2.1 in the stomach, 4.9 to 6.4
in the duodenum, 4.4 to 6.6 in the jejunum, and 6.5 to 7.4 in
the ileum (9). Furthermore, it generally takes approximately
85 min for a drug to reach the ileum (8). By the time the drug
reaches the ileum, the dissolution of the drug product is likely
complete if it meets the rapid dissolution criterion, i.e., no less
than 85% dissolved within 30 min. Therefore, it would appear
reasonable to redefine the pH range for BCS solubility class
boundary from 1.0–7.5 to 1.0–6.8 in alignment with dissolu-
tion pH ranges, which are pH 1.0, 4.5, and 6.8 buffers.
The dose volume of 250 mL seems a conservative esti-
mate of what actually is available in vivo for solubilization
and dissolution. The physiological volume of the small intes-
tine varies from 50 to 1100 mL with an average of 500 mL
under the fasted conditions (10). When administered with a
glass of water, the drug is immersed in approximately 250 mL
of liquid in the stomach. If the drug is not in solution in the
stomach, gastric emptying would then expose it to the small
intestine, and the solid drug would dissolve under the effect of
additional small intestinal fluid. However, because of the
large variability of the small intestinal volume, an appropriate
definition of the volume for solubility class boundary would
be difficult to set.
Another factor influencing in vivo solubility is bile salt/
micelle solubilization (11). Intestinal solubility is perhaps the
most important solubility because this is the absorbing region
for most drugs. Many acidic drugs whose solubility is low at
low pH are well absorbed. For example, most nonsteroidal
anti-inflammatory drugs, such as flurbiprofen, ketoprofen,
naproxen, and oxaprozin, are poorly soluble in the stomach
but are highly soluble in the distal intestine and their absolute
human bioavailabilities are 90% or higher, thus exhibiting
behavior similar to those of BCS Class I drugs (7).
The solubility classification is based on the ability of a
drug to dissolve in plain aqueous buffers. However, bile salts
are present in the small intestine, even in the fasted state. The
average bile salt concentration in the small intestine is esti-
mated to be approximately 5 mM (9). Based on physiological
factors, Dressman designed two kinds of media, one to simu-
late the fasted-state conditions in the small intestine and the
other to simulate the fed-state conditions in the small intes-
tine (9). These two media may be used in drug discovery and
development processes to assess in vivo solubility and disso-
lution and have the potential to be used in drug regulation,
i.e., dissolution methodology for bioequivalence demonstra-
tion using more physiologically relevant media, although
more extensive research is needed.
Other criteria, such as intrinsic dissolution rate, may be
useful in the classification of the biopharmaceutic properties
of drugs. The intrinsic dissolution method has been widely
used in pharmaceutical industries to characterize drug sub-
stances. Our recent data have shown that the intrinsic disso-
lution method is robust and easily determined. A good cor-
relation between the intrinsic dissolution rate and BCS solu-
bility classification was found for 17 BCS model drugs (12).
Thus, the intrinsic dissolution rate may be used when the
solubility of a drug cannot be accurately determined, al-
though more validation research needs to be conducted.
Potential of Redefining BCS Permeability Class Boundary
The permeability class boundary is based on the extent of
intestinal absorption (fraction of dose absorbed) of a drug
substance in humans or on measurements of the rate of mass
transfer across intestinal membranes. Under the current BCS
classification, a drug is considered to be highly permeable
when the fraction of dose absorbed is equal to or greater than
90%. The criterion of 90% for the fraction of dose absorbed
can be considered conservative because the experimentally
determined fraction of dose absorbed is seen to be less than
90% for many drugs that are generally considered completely
or well-absorbed. This suggests that a class boundary of 85%
might be appropriate in defining high permeability, although
it remains to be justified and debated.
Biowaiver Extension Potential to BCS Class II Drugs
BCS Class II drugs exhibit low solubility and high per-
meability characteristics. The scientific rationale for granting
biowaiver extension for Class II drugs is that their oral ab-
sorption is most likely limited by in vivo dissolution. If in vivo
dissolution can be estimated in vitro, it is possible to establish
an in vitro-in vivo correlation. In vitro dissolution methods
that mimic in vivo dissolution methods for Class II drugs are
appealing, but experimental methods can be difficult to de-
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sign and to validate because of the numerous in vivo pro-
cesses involved (9). Further, the intestinal absorption of Class
II drugs can be limited by its solubility (13). The key deter-
minant then is the solubility in the absorbing region of the
intestine. The solubilization can be affected by pH and/or
surfactants in this region. This suggests a potential to define
an intermediate solubility class for drugs that are soluble ei-
ther in the intestine or in the stomach.
The dissolution of formulations containing poorly
soluble drugs may require an addition of sodium lauryl sulfate
or other surfactants to mimic the solubilization in vivo and the
maintenance of sink conditions in vivo resulting from con-
tinuous absorption. For example, the recommended USP
dissolution media for medroxyprogesterone acetate tablet,
danazol capsule, carbamazepine tablet, and flutamide tablet
contain 0.5%, 0.75%, 1%, and 2% SLS, respectively (USP
24-NF19, 2001). Although the dissolution medium with vari-
ous surfactant concentrations may be adequate for the pur-
pose of product quality control, this is clearly not sufficient for
predicting in vivo dissolution. There is a need to do more
research to develop uniform dissolution media reflecting in
vivo dissolution conditions.
For BCS Class II drugs, excipients can, in principle, affect
both solubility and permeability. Some BCS Class II drugs,
such as HIV protease inhibitor amprenavir, require specific
formulation effort to enhance their solubility and permeabil-
ity (14). An excipient effect on solubility can be investigated
in vitro and ex vivo, and more research of this type is under-
way.
Biowaiver Extension Potential to BCS Class III Drugs
Drugs with high solubility and low permeability are clas-
sified as BCS Class III drugs. It has been suggested that bio-
waivers be extended to BCS Class III drugs with rapid disso-
lution property. It has been contended that there are equally
compelling reasons to grant biowaivers to Class III drugs as
there are for Class I drugs (6).
Scientific Rationale
The absorption of a Class III drug is likely limited by its
permeability and less dependent upon its formulation, and its
bioavailability may be determined by its in vivo permeability
pattern (6,15). If the dissolution of Class III products is rapid
under all physiological pH conditions, it can be expected that
they will behave like an oral solution in vivo. In vivo bio-
equivalence studies generally are waived for oral solution
drug products because the release of the drug from an oral
solution is self-evident (16).
Nevertheless, the absorption kinetics from the small in-
testine are influenced by a combination of physiological fac-
tors and biopharmaceutical properties such as gastrointestinal
motility, permeability, metabolism, dissolution, and the inter-
action/binding of drugs with excipients (18,19). A recent sur-
vey of the FDA data of over 10 BCS Class III drugs shows
that most commonly used excipients in solid dosage forms
have no significant effect on absorption. If the excipients used
in two pharmaceutically equivalent solid oral IR products do
not affect drug absorption and the two products dissolve very
rapidly in all physiologically relevant pH ranges (i.e., > 85%
in 15 min), there would appear to be no reason to believe that
these two products would not be bioequivalent.
Potential Excipient Effect on Motility and Permeability
Because Class III compounds often exhibit site-depen-
dent absorption properties (17,18), the transit time through
specific regions of the upper intestine may be critical for bio-
equivalence, suggesting a more stringent dissolution criterion
to ensure complete dissolution in the stomach. Certain excipi-
ents have been shown to influence gastrointestinal transit
time. For example, scintigraphy has indicated that sodium
acid pyrophosphate could reduce the small intestinal transit
time by as much as 43% compared to controls (19). Poorly
absorbed sugar alcohols, such as sorbitol and mannitol, can
also decrease small intestinal transit time (20). Therefore,
Class III oral drug products containing a significant amount of
transit-influencing excipients should be excluded from con-
sideration of biowaivers. Although most commonly used ex-
cipients in solid dosage forms are unlikely to influence the
gastrointestinal transit time significantly, the evidence by no
means is conclusive.
The effects of excipients on permeability have been re-
viewed in the literature (21). Excipients that can significantly
affect permeability in vitro include surfactants, fatty acids,
medium-chain glycerides, steroidal detergents, acyl carni-
tine and alkanoylcholines, N-acetylated non- amino acids,
chitosans, and other mucoadhesive polymers. Rege et al.
(22) investigated the effect of some formulation excipients
on Caco-2 permeability and found that several commonly
used IR formulation excipients did not modulate drug per-
meability across Caco-2 monolayers.
Dissolution
In vivo dissolution plays a more important role for Class
III IR drug products than it does for Class I drug products.
Dissolution tests with USP Apparatus I at 100 rpm (or USP
Apparatus II at 50 rpm) in a volume of 900 mL of various pH
media are recommended in the FDA guidance to evaluate the
product dissolution in vitro. For highly soluble and highly
permeable drugs, rapid dissolution in vitro (no less than 85%
in 30 min) can most likely ensure rapid in vivo dissolution.
However, the demonstration of rapid in vitro dissolution of
Class III drug products may not ensure rapid dissolution in
vivo simply because sink conditions may not exist under in
vivo conditions. To minimize the possibility of dissolution
behavior anomalies, it was found in our simulation studies
that it would be necessary to set a more rapid in vitro disso-
lution rate criterion of no less than 85% within 15 min for
Class III drugs (23).
Transporters
Numerous in vitro Caco-2 studies have suggested that
transporters may enhance or limit the absorption of many
drugs such as digoxin and HIV protease inhibitors, including
indinavir, ritonavir, and saquinavir (15,24). On the other
hand, many transporter substrates show complete intestinal
absorption and dose proportionality in vivo, implying that
transporters do not significantly influence in vivo absorption.
This apparent discrepancy between in vitro and in vivo
behavior may be explained by the potential inherent differ-
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ences in the two systems as well as by the experimental con-
ditions adopted in the comparisons. For example, a new
chemical entity was found to be a strong P-glycoprotein sub-
strate and was classified as a low permeability compound
based on in vitro Caco-2 studies. However, its absolute bio-
availability in humans was greater than 90%, and dose pro-
portionality was demonstrated over a 60-fold dose range. The
concentration of the compound in the in vitro Caco-2 studies
was approximately 3400-fold lower than the estimated con-
centration in vivo, which may account for the large discrep-
ancy between the in vivo and the in vitro findings of its per-
meability characteristics. Thus, in vitro studies must be ex-
trapolated to in vivo with great care. Nevertheless, the
potential impact of transporters on absorption should be thor-
oughly investigated and understood when considering bio-
waiver extensions.
Intermediate Permeability Classification
In general, the lower the permeability of a Class III drug,
the more significant the effect of excipients on absorption and
the higher the likelihood of bioinequivalence. Therefore, it
has been proposed to define an intermediate permeability
class so that drugs with 89% fraction of dose absorbed would
not be treated the same as drugs with 1% fraction of dose
absorbed. However, how to define the intermediate perme-
ability class remains to be addressed.
SUMMARY
The current BSC guidance issued by the FDA allows for
biowaivers based on conservative criteria. Possible new crite-
ria and class boundaries are proposed for additional biowaiv-
ers based on the underlying physiology of the gastrointestinal
tract. The proposed changes in new class boundaries for solu-
bility and permeability are as follows:
1. Narrow the required solubility pH range from 1.0–7.5
to 1.0–6.8.
2. Reduce the high permeability requirement from 90%
to 85%.
The following new criterion and potential biowaiver exten-
sion require more research:
1. Define a new intermediate permeability class bound-
ary.
2. Allow biowaivers for highly soluble and intermedi-
ately permeable drugs in IR solid oral dosage forms with no
less than 85% dissolved in 15 min in all physiologically rel-
evant dissolution media, provided these IR products contain
only known excipients that do not affect the oral drug ab-
sorption.
The following areas require more extensive research:
1. Increase the dose volume for solubility classification
to 500 mL.
2. Include bile salt in the solubility measurement.
3. Use the intrinsic dissolution method for solubility
classification.
4. Define an intermediate solubility class for BCS Class
II drugs.
5. Include surfactants in in vitro dissolution testing.
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